Healthcare Stocks

Noxopharm to Commence Veyonda®’s Clinical Trial in COVID-19 Patients in Europe

 Noxopharm to Commence Veyonda<sup>®</sup>’s Clinical Trial in COVID-19 Patients in Europe

Australian biotech, Noxopharm Limited (ASX:NOX) has announced an important milestone with formal approval for immediate initiation of Veyonda®’s clinical trial in COVID-19 patients in Europe. Following the key update, the Company’s...

Read More...
Noxopharm to Initiate COVID-19 Trial Program in Europe, Continues Discussions with FDA

Noxopharm to Initiate COVID-19 Trial Program in Europe, Continues Discussions with FDA

Australian clinical stage drug developer, Noxopharm Limited (ASX:NOX) notified in its latest update the commencement of NOXCOVID clinical trial program in Europe, focusing on safety and proof-of principle endpoints of Veyonda® as a potential tr...

Read More...
Noxopharm Presented Highly Encouraging Veyonda® Clinical Data at ASCO 2020 Annual Meeting

Noxopharm Presented Highly Encouraging Veyonda® Clinical Data at ASCO 2020 Annual Meeting

Summary Noxopharm presented two sets of clinical data concerning the development of Veyonda® as a treatment for end-stage prostate cancer at ASCO 2020 Annual Meeting. Highly encouraging interim data from the Phase 1b/2a LuPIN clinical trial...

Read More...
Noxopharm’s potential COVID-19 treatment - Lodges pre-IND Submission with FDA for Veyonda<sup>®</sup> Clinical Trial

Noxopharm’s potential COVID-19 treatment - Lodges pre-IND Submission with FDA for Veyonda® Clinical Trial

Marking a step forward, clinical-stage drug development company Noxopharm (ASX:NOX) has lodged a pre-IND (Investigational New Drug) submission with the U.S. Food and Drug Administration (FDA) for a Veyonda® clinical trial in COVID-19 (SARS-C...

Read More...
Noxopharm Confirms Abscopal Responses in DARRT-1 Patients

Noxopharm Confirms Abscopal Responses in DARRT-1 Patients

Biotech company Noxopharm Limited (ASX:NOX) possesses an exciting new potential treatment for end-stage prostate cancer as suggested by the latest radiographic review of DARRT-1 clinical study, supporting the Company’s belief in the anti-cancer...

Read More...
Noxopharm’s Breakthrough in Brain Cancer Program; Second Pipeline Drug Program Confirmed

Noxopharm’s Breakthrough in Brain Cancer Program; Second Pipeline Drug Program Confirmed

In a new development, clinical-stage oncology drug development player Noxopharm Limited (ASX:NOX) has confirmed that an isoflavonoid drug candidate has passed the proof-of-principle test for its brain cancer program in laboratory studies, paving the ...

Read More...
Noxopharm Aims to Test Veyonda® Against COVID-19, US FDA Approval To be Sought for Clinical Study

Noxopharm Aims to Test Veyonda® Against COVID-19, US FDA Approval To be Sought for Clinical Study

Clinical-stage Australian oncology drug development player Noxopharm (ASX:NOX) has revealed that the active ingredient in Veyonda® - idronoxil, blocks the STING (Stimulator of Interferon Genes) signalling pathway associated with the type of cellu...

Read More...
Noxopharm Investigating Idronoxil’s Potential in COVID-19 Treatment

Noxopharm Investigating Idronoxil’s Potential in COVID-19 Treatment

Australian oncology drug development company Noxopharm (ASX:NOX), along with the Hudson Institute of Medical Research in Melbourne, has identified anti-inflammatory properties of idronoxil, consistent with reducing a ‘cytokine storm’ whic...

Read More...
Noxopharm registered drug Veyonda® Granted 1st Allowed Patent Application, Advancing on Commercialisation Strategy

Noxopharm registered drug Veyonda® Granted 1st Allowed Patent Application, Advancing on Commercialisation Strategy

Australian clinical stage drug development company Noxopharm Limited (ASX:NOX) recently announced a significant milestone, that its potentially transformative anti-cancer drug candidate Veyonda® has been awarded first allowed patent application (...

Read More...
Noxopharm’s Veyonda® Granted IND for Sarcoma Patients.

Noxopharm’s Veyonda® Granted IND for Sarcoma Patients.

Latest LuPIN Trial Interim Results and an Alliance with Oncology Services Provider, GenesisCare Further Enhance Veyonda®’s Potential Commercial and Shareholder Value  Australian clinical-stage drug development company Noxopharm Limite...

Read More...
Noxopharm Seeks to Bring Veyonda® to Market as a First-in-class Drug to Boost the Effectiveness of Radiation Therapy in Prostate Cancer

Noxopharm Seeks to Bring Veyonda® to Market as a First-in-class Drug to Boost the Effectiveness of Radiation Therapy in Prostate Cancer

Noxopharm Limited (ASX:NOX), an Australian clinical stage biotechnology company with its focus on oncology, is known for developing a novel, potentially transformative and industry disruptive cancer drug treatment using its lead candidate, Veyonda&re...

Read More...
Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK